The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Quinolones: Action and Resistance Updated
Open accessAbstract
The quinolones trap DNA gyrase and DNA topoisomerase IV on DNA as complexes in which the DNA is broken but constrained by protein. Early studies suggested that drug binding occurs largely along helix-4 of the GyrA (gyrase) and ParC (topoisomerase IV) proteins. However, recent X-ray crystallography shows drug intercalating between the -1 and +1 nucleotides of cut DNA, with only one end of the drug extending to helix-4. These two models may reflect distinct structural steps in complex formation. A consequence of drug-enzyme-DNA complex formation is reversible inhibition of DNA replication; cell death arises from subsequent events in which bacterial chromosomes are fragmented through two poorly understood pathways. In one pathway, chromosome fragmentation stimulates excessive accumulation of highly toxic reactive oxygen species that are responsible for cell death. Quinolone resistance arises stepwise through selective amplification of mutants when drug concentrations are above the MIC and below the MPC, as observed with static agar plate assays, dynamic in vitro systems, and experimental infection of rabbits. The gap between MIC and MPC can be narrowed by compound design that should restrict the emergence of resistance. Resistance is likely to become increasingly important, since three types of plasmid-borne resistance have been reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics
Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A., & Collins, J. J. (2007) · Cell · doi:10.1016/j.cell.2007.06.049 · Cited by 2,982 · cited 1×
“coli following treatment with several lethal antimicrobials, including norfloxacin [91, 92].”
BackgroundCraig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“This pharmacodynamic index (AUC24/MIC) correlates empirically with favorable patient and microbiological outcome [129, 130].”
BackgroundDNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Self-citationQuinolone resistance from a transferable plasmid
Martínez-Martínez, L., Pascual, A., & Jacoby, G. A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07322-4 · Cited by 1,100
The importance of repairing stalled replication forks
Cox, M. M., Goodman, M. F., Kreuzer, K. N., Sherratt, D. J., Sandler, S. J., & Marians, K. J. (2000) · Nature · doi:10.1038/35003501 · Cited by 1,044
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
Robicsek, A., Strahilevitz, J., Jacoby, G. A., Macielag, M., Abbanat, D., Hye Park, C., Bush, K., & Hooper, D. C. (2006) · Nature Medicine · doi:10.1038/nm1347 · Cited by 1,013
The worldwide emergence of plasmid-mediated quinolone resistance
Robicsek, A., Jacoby, G. A., & Hooper, D. C. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70599-0 · Cited by 966
Mechanisms of Resistance to Quinolones
Jacoby, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/428052 · Cited by 924
Structure and mechanism of DNA topoisomerase II
Berger, J. M., Gamblin, S. J., Harrison, S. C., & Wang, J. C. (1996) · Nature · doi:10.1038/379225a0 · Cited by 859
Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., & Tomizawa, J.-I. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.4772 · Cited by 833
Sugino, A., Peebles, C. L., Kreuzer, K. N., & Cozzarelli, N. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.4767 · Cited by 784
Prevalence in the United States of aac(6 ′ ) - Ib - cr Encoding a Ciprofloxacin-Modifying Enzyme
Park, C. H., Robicsek, A., Jacoby, G. A., Sahm, D., & Hooper, D. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00915-06 · Cited by 757
Sieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance
Cirz, R. T., Chin, J. K., Andes, D. R., de Crécy-Lagard, V., Craig, W. A., & Romesberg, F. E. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030176 · Cited by 576
qnr Prevalence in Ceftazidime-Resistant Enterobacteriaceae Isolates from the United States
Robicsek, A., Strahilevitz, J., Sahm, D. F., Jacoby, G. A., & Hooper, D. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01647-05 · Cited by 569
New topoisomerase essential for chromosome segregation in E. coli
Kato, J.-I., Nishimura, Y., Imamura, R., Niki, H., Hiraga, S., & Suzuki, H. (1990) · Cell · doi:10.1016/0092-8674(90)90172-b · Cited by 566
Mechanism of plasmid-mediated quinolone resistance
Tran, J. H., & Jacoby, G. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082092899 · Cited by 564
Tumor Cell Death Induced by Topoisomerase-Targeting Drugs
Li, T.-K., & Liu, L. F. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.53 · Cited by 508
Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli
Dwyer, D. J., Kohanski, M. A., Hayete, B., & Collins, J. J. (2007) · Molecular Systems Biology · doi:10.1038/msb4100135 · Cited by 469
Plasmid-Mediated Quinolone Resistance in Clinical Isolates of Escherichia coli from Shanghai, China
Wang, M., Tran, J. H., Jacoby, G. A., Zhang, Y., Wang, F., & Hooper, D. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2242-2248.2003 · Cited by 467
Crystal structure of the breakage–reunion domain of DNA gyrase
Cabral, J. H. M., Jackson, A. P., Smith, C. V., Shikotra, N., Maxwell, A., & Liddington, R. C. (1997) · Nature · doi:10.1038/42294 · Cited by 456
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
Pan, X. S., Ambler, J., Mehtar, S., & Fisher, L. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2321 · Cited by 437
Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae
Nordmann, P., & Poirel, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki245 · Cited by 425
Recombinational repair and restart of damaged replication forks
McGlynn, P., & Lloyd, R. G. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm951 · Cited by 399
Zhao, X., & Drlica, K. (2001) · Clinical Infectious Diseases · doi:10.1086/321841 · Cited by 397
Self-citationLevine, C., Hiasa, H., & Marians, K. J. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00126-2 · Cited by 391
Self-citationMutant Selection Window Hypothesis Updated
Drlica, K., & Zhao, X. (2007) · Clinical Infectious Diseases · doi:10.1086/511642 · Cited by 383
Self-citationFerrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A., & Blanche, F. (1994) · Molecular Microbiology · doi:10.1111/j.1365-2958.1994.tb00458.x · Cited by 378
Efflux-Mediated Resistance to Fluoroquinolones in Gram-Negative Bacteria
Poole, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2233-2241.2000 · Cited by 371
Clostridium difficile Infection Caused by the Epidemic BI/NAP1/027 Strain
O'Connor, J. R., Johnson, S., & Gerding, D. N. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.073 · Cited by 357
Roles of Topoisomerases in Maintaining Steady-state DNA Supercoiling in Escherichia coli
Zechiedrich, E. L., Khodursky, A. B., Bachellier, S., Schneider, R., Chen, D., Lilley, D. M. J., & Cozzarelli, N. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8103 · Cited by 328
Multiple pathways process stalled replication forks
Michel, B., Grompone, G., Florès, M.-J., & Bidnenko, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401586101 · Cited by 322 · cited 1×
“When replication forks are stalled in vivo, they trigger ‘replication restart’ processes catalyzed by recombination proteins [80-83].”
BackgroundFluoroquinolones: Action and Resistance
Drlica, K., & Malik, M. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033452537 · Cited by 317
Self-citationStructural basis for gate-DNA recognition and bending by type IIA topoisomerases
Dong, K. C., & Berger, J. M. (2007) · Nature · doi:10.1038/nature06396 · Cited by 316
Blondeau, J. M., Zhao, X., Hansen, G., & Drlica, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.433-438.2001 · Cited by 314
Self-citationMulti-targeting by monotherapeutic antibacterials
Silver, L. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2202 · Cited by 311
Structural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases
Laponogov, I., Sohi, M. K., Veselkov, D. A., Pan, X.-S., Sawhney, R., Thompson, A. W., McAuley, K. E., Fisher, L. M., & Sanderson, M. R. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1604 · Cited by 304
A Fluoroquinolone Resistance Protein from Mycobacterium tuberculosis That Mimics DNA
Hegde, S. S., Vetting, M. W., Roderick, S. L., Mitchenall, L. A., Maxwell, A., Takiff, H. E., & Blanchard, J. S. (2005) · Science · doi:10.1126/science.1110699 · Cited by 291
Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli.
Zechiedrich, E. L., & Cozzarelli, N. R. (1995) · Genes & Development · doi:10.1101/gad.9.22.2859 · Cited by 290
Cloning of a Novel Gene for Quinolone Resistance from a Transferable Plasmid in Shigella flexneri 2b
Hata, M., Suzuki, M., Matsumoto, M., Takahashi, M., Sato, K., Ibe, S., & Sakae, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.801-803.2005 · Cited by 287
Interaction of the Plasmid-Encoded Quinolone Resistance Protein Qnr with Escherichia coli DNA Gyrase
Tran, J. H., Jacoby, G. A., & Hooper, D. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.118-125.2005 · Cited by 283
Dong, Y., Zhao, X., Domagala, J., & Drlica, K. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1756 · Cited by 278
Self-citationReplisome assembly and the direct restart of stalled replication forks
Heller, R. C., & Marians, K. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2058 · Cited by 268
Périchon, B., Courvalin, P., & Galimand, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00143-07 · Cited by 266
Plasmid-Mediated qepA Gene among Escherichia coli Clinical Isolates from Japan
Yamane, K., Wachino, J.-I., Suzuki, S., & Arakawa, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01137-07 · Cited by 253
Willmott, C. J., & Maxwell, A. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.1.126 · Cited by 252
DNA gyrase action involves the introduction of transient double-strand breaks into DNA.
Mizuuchi, K., Fisher, L. M., O'Dea, M. H., & Gellert, M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.4.1847 · Cited by 247
Wang, M., Sahm, D. F., Jacoby, G. A., & Hooper, D. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1295-1299.2004 · Cited by 243
Plasmid‐Mediated Quinolone Resistance in Non‐Typhi Serotypes of Salmonella enterica
Gay, K., Robicsek, A., Strahilevitz, J., Park, C. H., Jacoby, G., Barrett, T. J., Medalla, F., Chiller, T. M., & Hooper, D. C. (2006) · Clinical Infectious Diseases · doi:10.1086/505397 · Cited by 242
Krasin, F., & Hutchinson, F. (1977) · Journal of Molecular Biology · doi:10.1016/0022-2836(77)90120-6 · Cited by 237
Contribution of Oxidative Damage to Antimicrobial Lethality
Wang, X., & Zhao, X. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01087-08 · Cited by 222
Self-citationFirsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., & Zinner, S. H. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1604-1613.2003 · Cited by 215
Self-citationZechiedrich, E. L., Khodursky, A. B., & Cozzarelli, N. R. (1997) · Genes & Development · doi:10.1101/gad.11.19.2580 · Cited by 210
Biological roles of the Lon ATP-dependent protease
Tsilibaris, V., Maenhaut-Michel, G., & Van Melderen, L. (2006) · Research in Microbiology · doi:10.1016/j.resmic.2006.05.004 · Cited by 210
Zhao, X., & Drlica, K. (2002) · The Journal of Infectious Diseases · doi:10.1086/338571 · Cited by 210
Self-citationTsao, Y., Russo, A. A., Nyamuswa, G., SILBER, R. H., & Liu, L. F. (1993) · PubMed · Cited by 206
DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid
Snyder, M., & Drlica, K. (1979) · Journal of Molecular Biology · doi:10.1016/0022-2836(79)90077-9 · Cited by 203
Self-citationNalidixic Acid: an Antibacterial Paradox
Crumplin, G. C., & Smith, J. T. (1975) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.8.3.251 · Cited by 194
Vetting, M. W., Hegde, S. S., Fajardo, J. E., Fiser, A., Roderick, S. L., Takiff, H. E., & Blanchard, J. S. (2006) · Biochemistry · doi:10.1021/bi052130w · Cited by 190
The Structural Basis for Substrate Specificity in DNA Topoisomerase IV
Corbett, K. D., Schoeffler, A. J., Thomsen, N. D., & Berger, J. M. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.06.029 · Cited by 173
Tran, J. H., Jacoby, G. A., & Hooper, D. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.3050-3052.2005 · Cited by 167
Wu, J.-J., Ko, W.-C., Tsai, S.-H., & Yan, J.-J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01195-06 · Cited by 167
The C-terminal domain of DNA gyrase A adopts a DNA-bending β-pinwheel fold
Corbett, K. D., Shultzaberger, R. K., & Berger, J. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401595101 · Cited by 166
PLASMID-MEDIATED RESISTANCE TO NALIDIXIC ACID IN SHIGELLA DYSENTERIAE TYPE 1
Munshi, M. H., Haider, K., Rahaman, M. M., Sack, D., Ahmed, Z. U., & Morshed, M. G. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90957-3 · Cited by 166
The Mechanism of Inhibition of Topoisomerase IV by Quinolone Antibacterials
Khodursky, A. B., & Cozzarelli, N. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27668 · Cited by 163
Mechanisms Accounting for Fluoroquinolone Resistance in Escherichia coli Clinical Isolates
Morgan-Linnell, S. K., Becnel Boyd, L., Steffen, D., & Zechiedrich, L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00665-08 · Cited by 161
Willmott, C., Critchlow, S. E., Eperon, I. C., & Maxwell, A. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1586 · Cited by 160
Barnard, F. M., & Maxwell, A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.1994-2000.2001 · Cited by 160
Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance
Stratton, C. W. (2003) · Emerging infectious diseases · doi:10.3201/eid0901.020172 · Cited by 159
Zhou, J., Dong, Y., Zhao, X., Lee, S., Amin, A. G., Ramaswamy, S. V., Domagala, J. M., Musser, J. M., & Drlica, K. (2000) · The Journal of Infectious Diseases · doi:10.1086/315708 · Cited by 148
Self-citationBACTERIAL DIVERSITY BASED ON TYPE II DNA TOPOISOMERASE GENES
Huang, W. M. (1996) · Annual Review of Genetics · doi:10.1146/annurev.genet.30.1.79 · Cited by 144
Plasmid-Mediated Quinolone Resistance Pump QepA2 in an Escherichia coli Isolate from France
Cattoir, V., Poirel, L., & Nordmann, P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00638-08 · Cited by 140
Non-Target Gene Mutations in the Development of Fluoroquinolone Resistance in Escherichia coli
Kern, W. V., Oethinger, M. D., Jellen-Ritter, A., & Levy, S. B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.814-820.2000 · Cited by 140
Olofsson, S. K., Marcusson, L. L., Lindgren, P. K., Hughes, D., & Cars, O. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl135 · Cited by 139
Lee, I., & Suzuki, C. K. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.02.010 · Cited by 138
Hiasa, H., Yousef, D. O., & Marians, K. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.42.26424 · Cited by 136
Self-citationEfflux-Mediated Resistance to Fluoroquinolones in Gram-Positive Bacteria and the Mycobacteria
Poole, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2595-2599.2000 · Cited by 134
Fournier, B., Zhao, X., Lu, T., Drlica, K., & Hooper, D. C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2160-2165.2000 · Cited by 133
Self-citationTopoisomerase IV, alone, unknots DNA in E. coli
Deibler, R. W., Rahmati, S., & Zechiedrich, L. (2001) · Genes & Development · doi:10.1101/gad.872301 · Cited by 132
Yang, H. B., Chen, H., Yang, Q., Chen, M., & Wang, H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00830-08 · Cited by 127
Takei, M., Fukuda, H., Kishii, R., & Hosaka, M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3544-3547.2001 · Cited by 123
Poirel, L., Leviandier, C., & Nordmann, P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00597-06 · Cited by 122
Bast, D. J., Low, D. E., Duncan, C. L., Kilburn, L., Mandell, L. A., Davidson, R., & de Azavedo, J. C. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.3049-3054.2000 · Cited by 122
Montero, C. I., Mateu, G., Rodríguez, R., & Takiff, H. E. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3387-3392.2001 · Cited by 117
Ambrose, P. G., & Grasela, D. M. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(00)00185-1 · Cited by 117
Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms
Li, X.-Z. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.04.002 · Cited by 115
Metzler, K., Hansen, G. M., Hedlin, P. D., Harding, E., Drlica, K., & Blondeau, J. M. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.02.021 · Cited by 114
Self-citationCORKILL, J. E., Anson, J. J., & Hart, C. A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki388 · Cited by 105
Schentag, J. J. (1999) · Journal of Chemotherapy · doi:10.1179/joc.1999.11.6.426 · Cited by 103
Oppegaard, H., Steinum, T. M., & Wasteson, Y. (2001) · Applied and Environmental Microbiology · doi:10.1128/aem.67.8.3732-3734.2001 · Cited by 103
Induction and Inhibition of Ciprofloxacin Resistance-Conferring Mutations in Hypermutator Bacteria
Cirz, R. T., & Romesberg, F. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.220-225.2006 · Cited by 103
Wang, A., Yang, Y., Lu, Q., Wang, Y., Chen, Y., Deng, L., Ding, H., Deng, Q., Zhang, H., Wang, C., et al. (2008) · BMC Infectious Diseases · doi:10.1186/1471-2334-8-68 · Cited by 100
Topoisomerase II can unlink replicating DNA by precatenane removal
Lucas, I., Germe, T. R., Chevrier‐Miller, M., & Hyrien, O. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6509 · Cited by 100
Firsov, A. A., Smirnova, M. V., Lubenko, I. Y., Vostrov, S. N., Абрамович, П. Ю., & Zinner, S. H. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl387 · Cited by 100
Park, Y. J., Yu, J. K., Lee, S., Oh, E., & Woo, G. J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm266 · Cited by 100
DNA Cleavage Is Not Required for the Binding of Quinolone Drugs to the DNA Gyrase−DNA Complex
Critchlow, S. E., & Maxwell, A. (1996) · Biochemistry · doi:10.1021/bi9603175 · Cited by 89
Luo, H., Wan, K., & Wang, H. H. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.6.2970-2978.2005 · Cited by 86
Boyd, L. B., Maynard, M. J., Morgan‐Linnell, S. K., Banks, L. D., Sucgang, R., Hamill, R. J., Jimenez, J. R., Versalovic, J. A., Steffen, D. L., & Zechiedrich, L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00722-08 · Cited by 85
Marcusson, L. L., Olofsson, S. K., Lindgren, P. K., Cars, O., & Hughes, D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki136 · Cited by 85
The Interaction of Drugs with DNA Gyrase: A Model for the Molecular Basis of Quinolone Action
Heddle, J. G., Barnard, F. M., Wentzell, L. M., & Maxwell, A. (2000) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770008033048 · Cited by 83
Wentzell, L. M., & Maxwell, A. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4266 · Cited by 83
A unified anti-mutant dosing strategy
Zhao, X., & Drlica, K. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn229 · Cited by 81
Self-citationNovel oxazolidinone–quinolone hybrid antimicrobials
Gordeev, M. F., Hackbarth, C. J., Barbachyn, M. R., Banitt, L. S., Gage, J. R., Luehr, G. W., Gómez, M., Trias, J., Morin, S., Zurenko, G. E., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.07.021 · Cited by 81
Pohlhaus, J. R., & Kreuzer, K. N. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04638.x · Cited by 80
İnce, D., Zhang, X., Silver, L. C., & Hooper, D. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3370-3380.2002 · Cited by 80
Association of Plasmid-Mediated Quinolone Resistance with Extended-Spectrum β-Lactamase VEB-1
Poirel, L., Loo, M. V. D., Mammeri, H., & Nordmann, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.3091-3094.2005 · Cited by 77
Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L. R., Morris, T. W., Roche, E. D., Yan, D., & Lynch, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01649-07 · Cited by 76
Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments
Campion, J. J., McNamara, P. J., & Evans, M. E. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4733-4744.2004 · Cited by 74
Strahilevitz, J., & Hooper, D. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1949-1956.2005 · Cited by 67
A classification based framework for quantitative description of large-scale microarray data
Sangurdekar, D. P., Srienc, F., & Khodursky, A. B. (2006) · Genome biology · doi:10.1186/gb-2006-7-4-r32 · Cited by 67
Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa
Hansen, G. T., Zhao, X., Drlica, K., et al. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.10.005 · Cited by 66
Self-citationNazic, H., Poirel, L., & Nordmann, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.2146-2147.2005 · Cited by 64
Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L. R., Morris, T. W., Roche, E. D., Yan, D., & Lynch, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01651-07 · Cited by 62
Bandele, O. J., & Osheroff, N. (2008) · Biochemistry · doi:10.1021/bi800981j · Cited by 60
Kibbler, C. C. (2000) · UCL Discovery (University College London) · Cited by 55
Tran, T. P., Ellsworth, E. L., Sanchez, J. P., Watson, B. M., Stier, M. A., Showalter, H. D., Domagala, J. M., Shapiro, M. A., Joannides, E. T., Gracheck, S. J., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.005 · Cited by 54
Oppegard, L. M., Hamann, B. L., Streck, K. R., Ellis, K. C., Fiedler, H., Khodursky, A. B., & Hiasa, H. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01440-08 · Cited by 52
Self-citationUse of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones
German, N., Malik, M., Rosen, J. D., Drlica, K., & Kerns, R. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00330-08 · Cited by 49
Self-citationAnalysis of Pleiotropic Transcriptional Profiles: A Case Study of DNA Gyrase Inhibition
Jeong, K. S., Xie, Y., Hiasa, H., & Khodursky, A. B. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020152 · Cited by 45
Self-citationFihman, V., Lartigue, M.-F., Jacquier, H., Meunier, F., Schnepf, N., Raskine, L., Riahi, J., Pors, M.-J. S.-L., & Berçot, B. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.03.010 · Cited by 43
Li, X., Mariano, N., Rahal, J. J., Urban, C. M., & Drlica, K. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4460-4462.2004 · Cited by 41
Self-citationMalik, M., & Drlica, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00250-06 · Cited by 37
Self-citationHong, G., & Kreuzer, K. N. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.594-603.2000 · Cited by 35
Hong, G., & Kreuzer, K. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0835166100 · Cited by 34
Cheng, J., Thanassi, J. A., Thoma, C. L., Bradbury, B. J., Deshpande, M., & Pucci, M. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00158-07 · Cited by 32
Cordeiro, N. F., Robino, L., Medina, J., Seija, V., Bado, I., García, V., Berro, M., Pontet, J., López, L., Bazet, C., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00444-07 · Cited by 30
In Vitro Model of Mycobacterial Growth Arrest Using Nitric Oxide with Limited Air
Hussain, S., Malik, M., Shi, L., Gennaro, M. L., & Drlica, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00442-08 · Cited by 21
Self-citationMalik, M., Capecci, J., & Drlica, K. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00019-09 · Cited by 20
Self-citationThe RuvAB Branch Migration Complex Can Displace Topoisomerase IV·Quinolone·DNA Ternary Complexes
Shea, M. E., & Hiasa, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304217200 · Cited by 13
Self-citation
Cited by
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
Self-citationFluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success
Redgrave, L. S., Sutton, S. B., Webber, M. A., & Piddock, L. J. V. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.04.007 · Cited by 1,008
Pseudomonas Aeruginosa: Resistance to the Max
Poole, K. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00065 · Cited by 948
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Metadata
- Authors
- Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-08-01
- Volume
- 9
- Issue
- 11
- Pages
- 981-998
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2167787735
- Cited by
- 376
- References
- 133
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.